Fig. 3.
Fig. 3. Immunophenotypic erythroid abnormalities in MDS. / (A) Analysis gate used: the analysis gate used includes nucleated red cell precursors (CD45 dim to negative and low SSC) and is demonstrated in the boxed region of this bone marrow. (B) Healthy donor bone marrow: there is high-level staining for the transferrin receptor (FITC-CD71, x-axis) in the glycophorin A–positive (GLY A, y-axis) nucleated erythroid cells. (C) MDS patient bone marrow: FITC-CD71 (x-axis) versus PE anti–glycophorin A (y-axis). There is a broad spectrum of CD71 expression—from normal to very low. (D) MDS patient bone marrow: FITC-CD71 (x-axis) versus PE anti–glycophorin A (y-axis). There is decreased CD71 expression in the glycophorin A–positive cells.

Immunophenotypic erythroid abnormalities in MDS.

(A) Analysis gate used: the analysis gate used includes nucleated red cell precursors (CD45 dim to negative and low SSC) and is demonstrated in the boxed region of this bone marrow. (B) Healthy donor bone marrow: there is high-level staining for the transferrin receptor (FITC-CD71, x-axis) in the glycophorin A–positive (GLY A, y-axis) nucleated erythroid cells. (C) MDS patient bone marrow: FITC-CD71 (x-axis) versus PE anti–glycophorin A (y-axis). There is a broad spectrum of CD71 expression—from normal to very low. (D) MDS patient bone marrow: FITC-CD71 (x-axis) versus PE anti–glycophorin A (y-axis). There is decreased CD71 expression in the glycophorin A–positive cells.

Close Modal

or Create an Account

Close Modal
Close Modal